Bevacizumab 100 & 400 Equity Injection
PDF Leaflet Revision Date: 4 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including metastatic colorectal, breast, lung, and renal cell cancers.
Dosage (summary)
5-15 mg/kg IV every 2-3 weeks depending on cancer type.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; discontinue breastfeeding during treatment.
Key Drug Interactions
- Sunitinib
- Chemotherapy agents
Contraindications
- Hypersensitivity
- Untreated CNS metastases
- Pregnancy
- Lactation
Common side effects
- Hypertension
- Fatigue
- Diarrhoea
- Abdominal pain
Counselling Points
- Monitor blood pressure
- Report signs of bleeding
- Avoid pregnancy during treatment
Serious warnings
- Gastrointestinal perforations
- Arterial thromboembolism
- Wound healing complications
Important Disclaimer
The Bevacizumab 100 & 400 Equity Injection professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
